No Picture
News

Covid-19 roundup: Synairgen turns to post-hoc analyses after failed drug trial; EU terminates Valneva vaccine contract

After halting enrollment in an NIH-led Phase II/III study, and failing an earlier Phase III trial, UK-based Synairgen’s Covid-19 drug did show some promise in some select subgroups, the company said in its presentation of […]

No Picture
News

Inmagene Receives FDA IND Clearance for a Third Generation BTK Inhibitor Targeting Immunological Diseases

SAN DIEGO and SHANGHAI, May 15, 2022 /PRNewswire/ — Inmagene Biopharmaceuticals (“Inmagene”) announces that today the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application for the drug candidate IMG-004, a […]

No Picture
News

Pfizer’s $11.6B wager; TIGIT implosion; An unusual pharma-biotech pact; Inside a16z’s vision to reshape biotech; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up […]